metricas
covid
Buscar en
Neurología (English Edition)
Toda la web
Inicio Neurología (English Edition) The prevalence of cancer in patients with multiple sclerosis (MS) who received r...
Journal Information

Statistics

Follow this link to access the full text of the article

Original article
The prevalence of cancer in patients with multiple sclerosis (MS) who received rituximab: a systematic review and meta-analysis
La prevalencia de cáncer en pacientes con esclerosis múltiple (EM) que recibieron rituximab: una revisión sistemática y meta-análisis
O. Mirmosayyeba, V. Shaygannejada, N. Ebrahimia, H. Ghoshounia, M. Ghajarzadehb,
Corresponding author
a Department of Neurology, School of Medicine, Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
b Universal Council of Epidemiology (UCE), Universal Scientific Education and Research Network (USERN), Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran
Read
832
Times
was read the article
174
Total PDF
658
Total HTML
Share statistics
Article information
ISSN: 21735808
Original language: English
The statistics are updated each day
Year/Month Html Pdf Total
2024 November 25 2 27
2024 October 30 10 40
2024 September 32 7 39
2024 August 36 7 43
2024 July 31 1 32
2024 June 40 15 55
2024 May 19 8 27
2024 April 47 3 50
2024 March 50 8 58
2024 February 63 8 71
2024 January 32 4 36
2023 December 33 8 41
2023 November 53 18 71
2023 October 51 14 65
2023 September 15 4 19
2023 August 17 3 20
2023 July 6 11 17
2023 June 14 2 16
2023 May 40 4 44
2023 April 24 2 26
2023 March 0 3 3
2023 February 0 9 9
2023 January 0 5 5
2022 December 0 4 4
2022 November 0 12 12
2022 October 0 2 2
Show all

Follow this link to access the full text of the article

es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos